Bausch + Lomb Q1 2026 revenue $1.244B (+9% YoY), raises full-year guidance

Bausch & Lomb Corp

2026-Q1 EPS reported -$0.20 revenue$1,244,000,000

Revenue $1.244B, up 9% reported and 6% constant currency YoY; GAAP net loss narrowed to $71M from $212M.
Adjusted EBITDA (non-GAAP) $189M vs $98M prior year; adjusted EPS $0.05 vs -$0.15.
Raising 2026 revenue guidance to $5.42B-$5.52B (was $5.375B-$5.475B) and Adj. EBITDA ex-IPR&D to $1.01B-$1.06B.
Pharmaceuticals segment grew 12% constant currency; MIEBO (+33%) and XIIDRA (+30%) led growth.
Vision Care +5% constant currency; Surgical +1% constant currency; double-digit growth in daily SiHy lenses.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bausch & Lomb Corp reported the quarter ended March 31, 2026 results: revenue $1.244 billion, net income $71 million, EPS ($0.20). Guidance raised.

Period: the quarter ended March 31, 2026
Revenue: $1.244 billion
Net income: $71 million
EPS: ($0.20)
Guidance: raised
Result: reported results

Exact text from the filing

1933, as amended. --- EX-99.1 (EX-99.1) --- Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook • Revenue of $1.244 Billion • Revenue Grew 9% as Reported and 6% on a Constant Currency 1 Basis Compared to the First Quarter of 2025 • GAAP Net Loss Attributable to Bausch + Lomb Corporation of $71 Million

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Bausch & Lomb Corp filing history →

Source: SEC EDGAR

accession 0001860742-26-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.